{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T02:41:20Z","timestamp":1793500880980,"version":"4.5.0"},"reference-count":28,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2022,11,1]]},"abstract":"\n Importance<\/jats:title>\n Rituximab is a third-line option for refractory generalized myasthenia gravis (MG) based on empirical evidence, but its effect in new-onset disease is unknown.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To investigate the efficacy and safety of rituximab compared with placebo as an add-on to standard of care for MG.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This randomized, double-blind, placebo-controlled study took place throughout 48 weeks at 7 regional clinics in Sweden. Key inclusion criteria were age older than 18 years, onset of generalized symptoms within 12 months or less, and a Quantitative Myasthenia Gravis (QMG) score of 6 or more. Patients were screened from October 20, 2016, to March 2, 2020. Key exclusion criteria included pure ocular MG, suspected thymoma, previous thymectomy, and prior noncorticosteroid immunosuppressants or high doses of corticosteroids.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Participants were randomized 1:1 without stratification to a single intravenous infusion of 500 mg of rituximab or matching placebo.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Minimal disease manifestations at 16 weeks defined as a QMG score of 4 or less with prednisolone, 10 mg or less daily, and no rescue treatment.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Of 87 potentially eligible patients, 25 were randomized to rituximab (mean [SD] age, 67.4 [13.4] years; 7 [28%] female) and 22 to placebo (mean [SD] age, 58 [18.6] years; 7 [32%] female). Compared with placebo, a greater proportion with rituximab met the primary end point; 71% (17 of 24) in the rituximab group vs 29% (6 of 21) in the placebo group (Fisher exact test\n P<\/jats:italic>\n \u2009=\u2009.007; probability ratio, 2.48 [95% CI, 1.20-5.11]). Secondary end points, comparing changes in Myasthenia Gravis Activities of Daily Living and Myasthenia Gravis Quality of Life at 16 weeks with QMG at 24 weeks did not differ between groups with censoring for rescue treatment (per-protocol analysis) but were in favor of active treatment when rescue treatment was taken into account by worst rank imputation (post hoc analysis). Rescue treatments were also more frequent in the placebo arm (rituximab: 1 [4%]; placebo, 8 [36%]). One patient in the placebo arm had a myocardial infarction with cardiac arrest and 1 patient in the active arm experienced a fatal cardiac event.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n A single dose of 500 mg of rituximab was associated with greater probability of minimal MG manifestations and reduced need of rescue medications compared with placebo. Further studies are needed to address long-term benefit-risk balance with this treatment.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT02950155<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamaneurol.2022.2887","type":"journal-article","created":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T11:31:53Z","timestamp":1663587113000},"page":"1105","source":"Crossref","is-referenced-by-count":222,"title":["Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis"],"prefix":"10.1001","volume":"79","author":[{"given":"Fredrik","family":"Piehl","sequence":"first","affiliation":[{"name":"Department of Neurology, Karolinska University Hospital, Stockholm, Sweden"},{"name":"Neuroimmunology Unit, Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden"},{"name":"Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Eriksson-Dufva","sequence":"additional","affiliation":[{"name":"Department of Neurology, Karolinska University Hospital, Stockholm, Sweden"},{"name":"Neuroimmunology Unit, Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden"},{"name":"Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Budzianowska","sequence":"additional","affiliation":[{"name":"Department of Neurology and Rehabilitation, Ryhov Regional Hospital, J\u00f6nk\u00f6ping, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amalia","family":"Feresiadou","sequence":"additional","affiliation":[{"name":"Department of Neurology, Uppsala University Hospital, Uppsala, Sweden"},{"name":"Department of Medical Sciences, Section of Neurology, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Hansson","sequence":"additional","affiliation":[{"name":"Department of Clinical Science, Neurosciences, Ume\u00e5 University, Ume\u00e5, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max Albert","family":"Hietala","sequence":"additional","affiliation":[{"name":"Department of Neurology, Karolinska University Hospital, Stockholm, Sweden"},{"name":"Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"H\u00e5kansson","sequence":"additional","affiliation":[{"name":"Department of Neurology, Link\u00f6ping University Hospital, Link\u00f6ping, Sweden"},{"name":"Department of Biomedical and Clinical Sciences, Link\u00f6ping University, Link\u00f6ping, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rune","family":"Johansson","sequence":"additional","affiliation":[{"name":"Department of Neurology and Rehabilitation, Central Hospital Karlstad, Karlstad, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Jons","sequence":"additional","affiliation":[{"name":"Department of Neurology, Sahlgrenska University Hospital, Gothenburg, Sweden"},{"name":"Sahlgrenska Academy, Institute of Neuroscience and Physiology, Department of Clinical Neuroscience, Gothenburg University, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Kmezic","sequence":"additional","affiliation":[{"name":"Department of Neurology, Karolinska University Hospital, Stockholm, Sweden"},{"name":"Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Lindberg","sequence":"additional","affiliation":[{"name":"Department of Neurology, Sahlgrenska University Hospital, Gothenburg, Sweden"},{"name":"Sahlgrenska Academy, Institute of Neuroscience and Physiology, Department of Clinical Neuroscience, Gothenburg University, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Lindh","sequence":"additional","affiliation":[{"name":"Department of Neurology and Rehabilitation, Ryhov Regional Hospital, J\u00f6nk\u00f6ping, Sweden"},{"name":"Department of Biomedical and Clinical Sciences, Link\u00f6ping University, Link\u00f6ping, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Lundin","sequence":"additional","affiliation":[{"name":"Department of Neurology, Link\u00f6ping University Hospital, Link\u00f6ping, Sweden"},{"name":"Department of Biomedical and Clinical Sciences, Link\u00f6ping University, Link\u00f6ping, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingela","family":"Nygren","sequence":"additional","affiliation":[{"name":"Department of Neurology, Uppsala University Hospital, Uppsala, Sweden"},{"name":"Department of Medical Sciences, Section of Neurology, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Rostedt","family":"Punga","sequence":"additional","affiliation":[{"name":"Clinical Neurophysiology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden"},{"name":"Department of Neurophysiology, Uppsala University Hospital, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayomand","family":"Press","sequence":"additional","affiliation":[{"name":"Department of Neurology, Karolinska University Hospital, Stockholm, Sweden"},{"name":"Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Samuelsson","sequence":"additional","affiliation":[{"name":"Department of Neurology, Karolinska University Hospital, Stockholm, Sweden"},{"name":"Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Sundstr\u00f6m","sequence":"additional","affiliation":[{"name":"Department of Clinical Science, Neurosciences, Ume\u00e5 University, Ume\u00e5, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oskar","family":"Wickberg","sequence":"additional","affiliation":[{"name":"Department of Neurology and Rehabilitation, Central Hospital Karlstad, Karlstad, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Brauner","sequence":"additional","affiliation":[{"name":"Department of Neurology, Karolinska University Hospital, Stockholm, Sweden"},{"name":"Neuroimmunology Unit, Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden"},{"name":"Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Frisell","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"noi220053r1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis.","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"noi220053r2","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1111\/joim.12310","article-title":"The autoimmune spectrum of myasthenia gravis: a Swedish population-based study.","volume":"277","author":"Fang","year":"2015","journal-title":"J Intern Med"},{"issue":"2","key":"noi220053r3","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/mus.20950","article-title":"Lifetime course of myasthenia gravis.","volume":"37","author":"Grob","year":"2008","journal-title":"Muscle Nerve"},{"issue":"2","key":"noi220053r4","first-page":"255","article-title":"Clinical characteristics of refractory myasthenia gravis patients.","volume":"86","author":"Suh","year":"2013","journal-title":"Yale J Biol Med"},{"issue":"3","key":"noi220053r5","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for management of myasthenia gravis: 2020 update.","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"key":"noi220053r6","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/nyas.1993.681.issue-1","article-title":"A clinical therapeutic trial of cyclosporine in myasthenia gravis.","volume":"681","author":"Tindall","year":"1993","journal-title":"Ann N Y Acad Sci"},{"issue":"6","key":"noi220053r7","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","article-title":"A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis.","volume":"50","author":"Palace","year":"1998","journal-title":"Neurology"},{"issue":"6","key":"noi220053r8","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1212\/01.wnl.0000312374.95186.cc","article-title":"An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis.","volume":"71","author":"Sanders","year":"2008","journal-title":"Neurology"},{"issue":"6","key":"noi220053r9","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1212\/01.wnl.0000312373.67493.7f","article-title":"A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis.","volume":"71","author":"Muscle Study Group","year":"2008","journal-title":"Neurology"},{"issue":"9","key":"noi220053r10","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1136\/jnnp-2011-300148","article-title":"Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis.","volume":"82","author":"Yoshikawa","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"noi220053r11","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1212\/WNL.0000000000002795","article-title":"A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis.","volume":"87","author":"Pasnoor","year":"2016","journal-title":"Neurology"},{"issue":"5","key":"noi220053r12","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1055\/s-0036-1586265","article-title":"Myasthenia gravis.","volume":"36","author":"Drachman","year":"2016","journal-title":"Semin Neurol"},{"issue":"2","key":"noi220053r13","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41582-018-0110-z","article-title":"Immunotherapy in myasthenia gravis in the era of biologics.","volume":"15","author":"Dalakas","year":"2019","journal-title":"Nat Rev Neurol"},{"issue":"4","key":"noi220053r14","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1007\/s00415-019-09667-5","article-title":"Frequency and clinical features of treatment-refractory myasthenia gravis.","volume":"267","author":"Rath","year":"2020","journal-title":"J Neurol"},{"issue":"14","key":"noi220053r15","doi-asserted-by":"publisher","first-page":"e1382","DOI":"10.1212\/WNL.0000000000012604","article-title":"Patient-reported symptom severity in a nationwide myasthenia gravis cohort: cross-sectional analysis of the Swedish GEMG Study.","volume":"97","author":"Petersson","year":"2021","journal-title":"Neurology"},{"issue":"2","key":"noi220053r16","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S1474-4422(21)00463-4","article-title":"Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders.","volume":"21","author":"Verschuuren","year":"2022","journal-title":"Lancet Neurol"},{"issue":"12","key":"noi220053r17","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol"},{"issue":"3","key":"noi220053r18","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/s41573-020-00092-2","article-title":"B cell depletion therapies in autoimmune disease: advances and mechanistic insights.","volume":"20","author":"Lee","year":"2021","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"noi220053r19","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001116","article-title":"IgG4-mediated neurologic autoimmunities: understanding the pathogenicity of IgG4, ineffectiveness of IVIg, and long-lasting benefits of anti-B cell therapies.","volume":"9","author":"Dalakas","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"8","key":"noi220053r20","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1001\/jamaneurol.2020.0851","article-title":"Comparison between rituximab treatment for new-onset generalized myasthenia gravis and refractory generalized myasthenia gravis.","volume":"77","author":"Brauner","year":"2020","journal-title":"JAMA Neurol"},{"issue":"10","key":"noi220053r21","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1212\/WNL.0000000000004341","article-title":"Rituximab as treatment for anti-MuSK myasthenia gravis: multicenter blinded prospective review.","volume":"89","author":"Hehir","year":"2017","journal-title":"Neurology"},{"key":"noi220053r22","article-title":"Phase 2 trial of rituximab in acetylcholine receptor antibody-positive generalized myasthenia gravis: the BeatMG Study.","author":"Nowak","year":"2021","journal-title":"Neurology"},{"issue":"20","key":"noi220053r23","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1212\/WNL.0000000000003331","article-title":"Rituximab in multiple sclerosis: a retrospective observational study on safety and efficacy.","volume":"87","author":"Salzer","year":"2016","journal-title":"Neurology"},{"issue":"2","key":"noi220053r24","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","article-title":"Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies.","volume":"77","author":"Luna","year":"2020","journal-title":"JAMA Neurol"},{"issue":"3","key":"noi220053r25","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1093\/cvr\/cvab113","article-title":"Rituximab in patients with acute ST-elevation myocardial infarction: an experimental medicine safety study.","volume":"118","author":"Zhao","year":"2022","journal-title":"Cardiovasc Res"},{"issue":"3-4","key":"noi220053r26","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1080\/21678421.2021.1946084","article-title":"ALS patients with concurrent neuroinflammatory disorders; a nationwide clinical records study.","volume":"23","author":"Longinetti","year":"2022","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"1","key":"noi220053r27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1001\/archneur.56.1.25","article-title":"Late-onset myasthenia gravis: a changing scene.","volume":"56","author":"Aarli","year":"1999","journal-title":"Arch Neurol"},{"issue":"5","key":"noi220053r28","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S1474-4422(09)70063-8","article-title":"Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity.","volume":"8","author":"Meriggioli","year":"2009","journal-title":"Lancet Neurol"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2796552\/jamaneurology_piehl_2022_oi_220053_1667929381.88565.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T11:10:42Z","timestamp":1668424242000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2796552"}},"subtitle":["The RINOMAX Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2022,11,1]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2022.2887","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11,1]]}}}